Lanzone, Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities, Current Pharmaceutical Design, vol
Weight management GLP-1 deprescribing Does the science support it
Kurtzeborn said it took her months to recover, and it was almost two years before she was willing to try a weight-loss drug again
Mitral Cells of the Olfactory Bulb Perform Metabolic Sensing and Are Disrupted by Obesity at the Level of the Kv1.3 Ion Channel
Common signs of NAION include: Sudden, unilateral painless loss of vision Visual field defect (usually altitudinal) Blurred vision Dyschromatopsia (new onset impairment or loss of color vision) Relative afferent pupillary defect Optic disc swelling with or without hemorrhages A patient starting a GLP-1RAespecially if they have diabetes or age-related macular degeneration should have an in-person, comprehensive, dilated eye examination either within the 12 months prior to starting therapy or a baseline examination within one month of initiating therapy
Differential Effects of Glucagon-Like Peptide-1 Receptor Agonists on Heart Rate
